GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (BSP:I2TC34) » Definitions » 5-Year Yield-on-Cost %

Intra-Cellular Therapies (BSP:I2TC34) 5-Year Yield-on-Cost % : 0.00 (As of Jun. 09, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Intra-Cellular Therapies 5-Year Yield-on-Cost %?

Intra-Cellular Therapies's yield on cost for the quarter that ended in Mar. 2024 was 0.00.


The historical rank and industry rank for Intra-Cellular Therapies's 5-Year Yield-on-Cost % or its related term are showing as below:



BSP:I2TC34's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.265
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Intra-Cellular Therapies's 5-Year Yield-on-Cost %

For the Drug Manufacturers - Specialty & Generic subindustry, Intra-Cellular Therapies's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intra-Cellular Therapies's 5-Year Yield-on-Cost % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intra-Cellular Therapies's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Intra-Cellular Therapies's 5-Year Yield-on-Cost % falls into.



Intra-Cellular Therapies 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Intra-Cellular Therapies is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Intra-Cellular Therapies  (BSP:I2TC34) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Intra-Cellular Therapies 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Intra-Cellular Therapies (BSP:I2TC34) Business Description

Traded in Other Exchanges
Address
430 East 29th Street, New York, NY, USA, 10016
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Intra-Cellular Therapies (BSP:I2TC34) Headlines

No Headlines